Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Does adjuvant zoledronate reduce recurrence in patients with high-risk localised breast cancer

Trial Profile

Does adjuvant zoledronate reduce recurrence in patients with high-risk localised breast cancer

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 07 Feb 2018

At a glance

  • Drugs Zoledronic acid (Primary) ; Antineoplastics
  • Indications Early breast cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms AZURE
  • Most Recent Events

    • 31 Aug 2018 Biomarkers information updated
    • 07 Feb 2018 Results of a study assessing predictive role of serum bone biomarkers in identifying patients with a high risk of developing bone metastasis published in the Journal of the National Cancer Institute
    • 01 Feb 2017 This trial was completed in Spain, as per European Clinical Trials Database record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top